BLUE Share Price Performance
US$4.97
-3.14 (-38.75%)
37.9% undervalued intrinsic discount
US$8.00
Fair Value
Price US$4.97
AnalystConsensusTarget US$8.00
Fair ValueUS$8.00
Share PriceUS$4.97
37.9% undervalued intrinsic discount
bluebird bio, Inc. Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 17 Fair Values set on narratives written by author
BLUE Community Narratives
AN
Fair Value US$8 23.5% undervalued intrinsic discount
Patient Starts And Capacity Expansion Will Achieve Breakeven
0users have liked this narrative
0users have commented on this narrative
12users have followed this narrative
Patient Starts And Capacity Expansion Will Achieve Breakeven
Key Takeaways Sustained patient demand and operational efficiency improvements are poised to enhance revenue growth and financial stability by driving cash flow breakeven. Strategic financing and manufacturing capacity expansions support commercialization success and strengthen future revenue prospects.Read more
0users have liked this narrative
0users have commented on this narrative
12users have followed this narrative
AN
US$8
23.5% undervalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue growth
61.15% p.a.
Profit Margin
15.87%
Future PE
1.62x
Share price in 2028
US$8.92
Snowflake Analysis
bluebird bio, Inc. Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
n/a
- -20.42
- 27.12%
- -192.39%
- -175.5%
About BLUE
- Founded
- 1992
- Employees
- 248
- CEO
- WebsiteView website
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for curative severe genetic diseases in the United States. The company’s product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; LYFGENIA (lovotibeglogene autotemcel) for the treatment of sickle cell disease (SCD) and a history of vaso-occlusive events; and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. Its clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.
